Table 2.
Risks of primary outcomes for patients on different antihypertensive therapies compared to those without.
| Antihypertensive Therapy | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | |
| ARB (+)/ARB (−) | 0.67 (0.45, 0.99) | 0.047 | 0.66 (0.44, 0.98) | 0.040 | 0.53 (0.34, 0.83) | 0.006 |
| ACEI (+)/ACEI (−) | 1.24 (0.95, 1.61) | 0.155 | 1.22 (0.94, 1.59) | 0.126 | 1.19 (0.91, 1.54) | 0.209 |
| CCB (+)/CCB (−) | 1.21 (0.86, 1.70) | 0.268 | 1.27 (0.90, 1.78) | 0.173 | 1.23 (0.87, 1.73) | 0.245 |
| TD (+)/TD (−) | 0.89 (0.66, 1.23) | 0.508 | 0.90 (0.66, 1.23) | 0.503 | 0.88 (0.64, 1.21) | 0.438 |
Model 1: unadjusted. Model 2: Adjusted for baseline age and gender. Model 3: Added race, education, Body Mass Index (BMI), smoking history, systolic and dilated blood pressure, HbA1c level, lipid level (low-density lipoprotein, high-density lipoprotein and triglyceride), therapies, previous heart failure, previous CVD, sulfonylureas, biguanides, meglitinide, alpha-glucosidase inhibitors, thiazolidinediones, regular insulins and statins to model 2. Abbreviations: ARB, angiotensin receptor blocker; ACEI, angiotensin-converting-enzyme inhibitor; CCB, calcium channel blocker; TD, thiazide diuretics; HR, hazard ratio; CI, confidence interval. ARB (+), patients treated with ARB; ARB (−), patients treated without ARB; ACEI (+), patients treated with ACEI; ACEI (−), patients treated without ACEI; CCB (+), patients treated with CCB; CCB (−), patients treated without CCB; TD (+), patients treated with TD; TD (−), patients treated without TD.